Literature DB >> 16614951

Prevalence of irritable bowel syndrome and depression in fibromyalgia.

Jayde E Kurland1, Walter J Coyle, Anne Winkler, Elizabeth Zable.   

Abstract

The purpose of this study was to determine the point prevalence of depressive symptoms, using the PRIME-MD questionnaire, and irritable bowel syndrome (IBS), while comparing the Rome II to the Rome I criteria, in patients with fibromyalgia (FM) and rheumatologic controls in an outpatient setting. The prevalence of IBS in FM patients (n = 105) was 63% by Rome I and 81% by Rome II criteria. The prevalence of IBS in controls (n = 62) was 15% by Rome I and 24% by Rome II criteria (FM vs. control; P < 0.001). Depressive symptoms were met in 40% of FM patients and 8% of controls (P < 0.001). The coexistence of IBS and depressive symptoms in the FM patients was 31% (Rome I) and 34% (Rome II). The prevalence of IBS and depressive symptoms was higher in FM patients compared to the control population. Identification of IBS and depressive symptoms in FM patients might enable clinicians to better meet the needs of this patient population.

Entities:  

Mesh:

Year:  2006        PMID: 16614951     DOI: 10.1007/s10620-006-3154-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

2.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

3.  Regional cerebral activity in normal and pathological perception of visceral pain.

Authors:  D H Silverman; J A Munakata; H Ennes; M A Mandelkern; C K Hoh; E A Mayer
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

4.  Splitting irritable bowel syndrome: from original Rome to Rome II criteria.

Authors:  Fermin Mearin; Montse Roset; Xavier Badía; Agustin Balboa; Eva Baró; Julio Ponce; Manuel Díaz-Rubio; Ellen Caldwell; Mercedes Cucala; Arturo Fueyo; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

5.  Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors.

Authors:  Thorsten Giesecke; David A Williams; Richard E Harris; Thomas R Cupps; Xiaoming Tian; Thomas X Tian; Richard H Gracely; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2003-10

6.  Bowel dysfunction in fibromyalgia syndrome.

Authors:  G Triadafilopoulos; R W Simms; D L Goldenberg
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

7.  Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia.

Authors:  Lin Chang; Steve Berman; Emeran A Mayer; Brandall Suyenobu; Stuart Derbyshire; Bruce Naliboff; Brent Vogt; Leah FitzGerald; Mark A Mandelkern
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

8.  Assessing depression in fibromyalgia patients.

Authors:  C S Burckhardt; C A O'Reilly; A N Wiens; S R Clark; S M Campbell; R M Bennett
Journal:  Arthritis Care Res       Date:  1994-03

9.  Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype.

Authors:  Fermín Mearin; Agustín Balboa; Xavier Badía; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Montse Roset; Nicholas J Talley
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.566

10.  Fibromyalgic syndrome: depression and abnormal illness behavior. Multicenter investigation.

Authors:  M Ercolani; G Trombini; R Chattat; C Cervini; G Piergiacomi; F Salaffi; S Zeni; R Marcolongo
Journal:  Psychother Psychosom       Date:  1994       Impact factor: 17.659

View more
  24 in total

1.  The development and psychometric validation of the central sensitization inventory.

Authors:  Tom G Mayer; Randy Neblett; Howard Cohen; Krista J Howard; Yun H Choi; Mark J Williams; Yoheli Perez; Robert J Gatchel
Journal:  Pain Pract       Date:  2011-09-27       Impact factor: 3.183

2.  Further validation of a model of fibromyalgia syndrome in the rat.

Authors:  Paul G Green; Pedro Alvarez; Robert W Gear; Dennis Mendoza; Jon D Levine
Journal:  J Pain       Date:  2011-04-09       Impact factor: 5.820

3.  Celiac symptoms in patients with fibromyalgia: a cross-sectional study.

Authors:  Juan Miguel García-Leiva; Jorge Luis Ordóñez Carrasco; Mahmoud Slim; Elena P Calandre
Journal:  Rheumatol Int       Date:  2014-08-15       Impact factor: 2.631

Review 4.  An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms.

Authors:  Mahmoud Slim; Elena Pita Calandre; Fernando Rico-Villademoros
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

5.  Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey.

Authors:  Esme Fuller-Thomson; Jodie Nimigon-Young; Sarah Brennenstuhl
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

6.  Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial.

Authors:  Dennis C Ang; Janna Hilligoss; Timothy Stump
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

Review 7.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

Review 8.  Sex differences and hormonal modulation of deep tissue pain.

Authors:  Richard J Traub; Yaping Ji
Journal:  Front Neuroendocrinol       Date:  2013-07-17       Impact factor: 8.606

Review 9.  Irritable bowel syndrome: relations with functional, mental, and somatoform disorders.

Authors:  Constanze Hausteiner-Wiehle; Peter Henningsen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 10.  From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.

Authors:  Yvette Taché; Stefan Brunnhuber
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.